These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 3162680)
41. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia. Vega GL; Grundy SM J Intern Med; 1991 Oct; 230(4):341-50. PubMed ID: 1919427 [TBL] [Abstract][Full Text] [Related]
42. Catabolism of very-low-density lipoproteins in subjects with broad beta disease: comparison with endogenous hypertriglyceridemia. Kushwaha RS; Chait A; Hazzard WR J Lab Clin Med; 1982 Jan; 99(1):15-24. PubMed ID: 6948063 [TBL] [Abstract][Full Text] [Related]
43. Isolation and characterization of apolipoprotein B-48 and B-100 very low density lipoproteins from type III hyperlipoproteinemic subjects. Milne RW; Weech PK; Blanchette L; Davignon J; Alaupovic P; Marcel YL J Clin Invest; 1984 Mar; 73(3):816-23. PubMed ID: 6368590 [TBL] [Abstract][Full Text] [Related]
44. Regulation of apolipoprotein B-containing lipoproteins by dietary soluble fiber in guinea pigs. Fernandez ML; Vergara-Jimenez M; Conde K; Behr T; Abdel-Fattah G Am J Clin Nutr; 1997 Mar; 65(3):814-22. PubMed ID: 9062534 [TBL] [Abstract][Full Text] [Related]
45. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202 [TBL] [Abstract][Full Text] [Related]
46. Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease. Kesäniemi YA; Beltz WF; Grundy SM J Clin Invest; 1985 Aug; 76(2):586-95. PubMed ID: 3861622 [TBL] [Abstract][Full Text] [Related]
47. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523 [TBL] [Abstract][Full Text] [Related]
48. Hypercholesterolemia in postmenopausal women. Metabolic defects and response to low-dose lovastatin. Arca M; Vega GL; Grundy SM JAMA; 1994 Feb; 271(6):453-9. PubMed ID: 8295321 [TBL] [Abstract][Full Text] [Related]
49. Effect of lovastatin on the secretion of very low density lipoprotein lipids and apolipoprotein B in the hypertriglyceridemic Zucker obese rat. Kasim SE; Elovson J; Khilnani S; Almario RU; Jen KL Atherosclerosis; 1993 Dec; 104(1-2):147-52. PubMed ID: 8141838 [TBL] [Abstract][Full Text] [Related]
50. Preliminary report: treatment of type 3 hyperlipoproteinemia with mevinolin. East CA; Grundy SM; Bilheimer DW Metabolism; 1986 Feb; 35(2):97-8. PubMed ID: 3633017 [TBL] [Abstract][Full Text] [Related]
51. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788 [TBL] [Abstract][Full Text] [Related]
52. Evaluation of the Non-HDL Cholesterol to Apolipoprotein B Ratio as a Screening Test for Dysbetalipoproteinemia. Boot CS; Middling E; Allen J; Neely RDG Clin Chem; 2019 Feb; 65(2):313-320. PubMed ID: 30538126 [TBL] [Abstract][Full Text] [Related]
53. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Kissebah AH; Alfarsi S; Evans DJ; Adams PW Diabetes; 1982 Mar; 31(3):217-25. PubMed ID: 7152129 [TBL] [Abstract][Full Text] [Related]
54. Treatment of type III hyperlipoproteinemia with four different treatment regimens. Hoogwerf BJ; Bantle JP; Kuba K; Frantz ID; Hunninghake DB Atherosclerosis; 1984; 51(2-3):251-9. PubMed ID: 6588975 [TBL] [Abstract][Full Text] [Related]
55. Defective hepatic lipoprotein receptor binding of beta-very low density lipoproteins from type III hyperlipoproteinemic patients. Importance of apolipoprotein E. Hui DY; Innerarity TL; Mahley RW J Biol Chem; 1984 Jan; 259(2):860-9. PubMed ID: 6319389 [TBL] [Abstract][Full Text] [Related]
56. Lipoproteins in familial dysbetalipoproteinemia. Variation of serum cholesterol level associated with VLDL concentration. Zhao SP; Smelt AH; Leuven JA; van den Maagdenberg AM; van der Laarse A; van 't Hooft FM Arterioscler Thromb; 1993 Feb; 13(2):316-23. PubMed ID: 8427867 [TBL] [Abstract][Full Text] [Related]
58. Metabolism of apolipoprotein B-100 and of triglyceride-rich lipoprotein particles in the absence of functional lipoprotein lipase. Pacy PJ; Mitropoulos KA; Venkatesan S; Watts GF; Reeves BE; Halliday D Atherosclerosis; 1993 Nov; 103(2):231-43. PubMed ID: 8292098 [TBL] [Abstract][Full Text] [Related]
59. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786 [TBL] [Abstract][Full Text] [Related]
60. Regulation of very low density lipoprotein apo B metabolism by dietary fat saturation and chain length in the guinea pig. Abdel-Fattah G; Fernandez ML; McNamara DJ Lipids; 1998 Jan; 33(1):23-31. PubMed ID: 9470170 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]